Yuko Oya

Differential Crizotinib Response Duration Among <i>ALK</i> Fusion Variants in <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Tatsuya Yoshida, Yuko Oya, Kosuke Tanaka et al. · Journal of Clinical Oncology · 2016 · 250 citations

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda et al. · Oncotarget · 2017 · 108 citations · Full text

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 81 citations

Real-world Setting, Medicine, Pathology +8

EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma

Kosuke Tanaka, Toyoaki Hida, Yuko Oya et al. · Journal of Thoracic Oncology · 2015 · 67 citations · Full text

Egfr Mutation Impact, Radiation Therapy, Medicine +8

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i> -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Kyung-A Song, Yasuyuki Hosono, Crystal Turner et al. · Clinical Cancer Research · 2018 · 65 citations